

# Chunyan Gu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1153177/chunyan-gu-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

320  
citations

12  
h-index

17  
g-index

37  
ext. papers

634  
ext. citations

9  
avg, IF

4.13  
L-index

#	Paper	IF	Citations
32	Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer.. <i>Pharmacology &amp; Therapeutics</i> , <b>2022</b> , 234, 108123	13.9	3
31	AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 11	12.8	2
30	Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication.. <i>Clinical and Translational Medicine</i> , <b>2022</b> , 12, e684	5.7	1
29	A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 85	12.8	0
28	BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 361	21	5
27	Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice Decreasing Metabolic Ornithine. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 779562	5.3	0
26	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 54	22.4	17
25	Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 675939	5.7	3
24	CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 90	22.4	3
23	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. <i>Molecular Cancer</i> , <b>2021</b> , 20, 84	42.1	9
22	RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 1803-1807	10.7	5
21	Review on circular RNAs and new insights into their roles in cancer. <i>Computational and Structural Biotechnology Journal</i> , <b>2021</b> , 19, 910-928	6.8	43
20	Suppression of steroid 5 $\beta$ reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 206	9.8	5
19	Alternative splicing and cancer: a systematic review. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 78	21	34
18	Research Advances on Acupuncture Analgesia. <i>The American Journal of Chinese Medicine</i> , <b>2020</b> , 48, 245-258		17
17	Bioactive Compounds from . Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 959-973	4.4	8
16	HUANGKUISIWUFANG inhibits pyruvate dehydrogenase to improve glomerular injury in anti-Thy1 nephritis model. <i>Journal of Ethnopharmacology</i> , <b>2020</b> , 253, 112682	5	2

15	CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	
14	Steroid 5 $\beta$ Reductase Type I Induces Cell Viability and Migration via Nuclear Factor- $\kappa$ B/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1501	5.3	2
13	Lycium barbarum polysaccharides attenuate rat anti-Thy-1 glomerulonephritis through mediating pyruvate dehydrogenase. <i>Biomedicine and Pharmacotherapy</i> , <b>2019</b> , 116, 109020	7.5	6
12	Iron metabolism and its contribution to cancer (Review). <i>International Journal of Oncology</i> , <b>2019</b> , 54, 1143-1154	4.4	33
11	Insights into a Crucial Role of TRIP13 in Human Cancer. <i>Computational and Structural Biotechnology Journal</i> , <b>2019</b> , 17, 854-861	6.8	19
10	RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiquitination in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3068-3068	2.2	
9	The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 5586-5586		
8	Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 22	7	13
7	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. <i>BMC Cancer</i> , <b>2018</b> , 18, 1152	4.8	9
6	ZiBuPiYin recipe improves cognitive decline by regulating gut microbiota in Zucker diabetic fatty rats. <i>Oncotarget</i> , <b>2017</b> , 8, 27693-27703	3.3	16
5	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. <i>Oncotarget</i> , <b>2017</b> , 8, 56858-56867	3.3	4
4	Chromosomal instability and acquired drug resistance in multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 78234-78244	3.3	17
3	Deciphering bacterial community changes in zucker diabetic fatty rats based on 16S rRNA gene sequences analysis. <i>Oncotarget</i> , <b>2016</b> , 7, 48941-48952	3.3	12
2	An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 311, F852-F863	4.3	13
1	BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. <i>Medical Oncology</i> , <b>2015</b> , 32, 81	3.7	14